TY - JOUR
T1 - Attenuating the mortality risk of High serum uric acid
T2 - The role of physical activity underused
AU - Chen, Jiunn Horng
AU - Wen, Chi Pang
AU - Wu, Shiuan Bei
AU - Lan, Joung Liang
AU - Tsai, Min Kuang
AU - Tai, Ya Ping
AU - Lee, June Han
AU - Hsu, Chih Cheng
AU - Tsao, Chwen Keng
AU - Wai, Jackson Pui Man
AU - Chiang, Po Huang
AU - Pan, Wen Han
AU - Hsiung, Chao Agnes
PY - 2015/11/1
Y1 - 2015/11/1
N2 - Background: High serum uric acid (sUA) has been associated with increased mortality risks, but its clinical treatment varied with potential side effects. The role of physical activity has received limited attention. Methods: A cohort, consisting of 467 976 adults, who went through a standard health screening programme, with questionnaire and fasting blood samples, was successively recruited between 1996 and 2008. High sUA is defined as uric acid above 7.0 mg/dL. Leisure time physical activity level was self-reported, with fully active defined as those with 30 min per day for at least 5days a week.National death file identified 12 228 deaths with a median follow-up of 8.5 years.Cox proportional model was used to analyse HRs, and 12 variables were controlled, including medical history, life style and risk factors. Findings High sUA constituted one quarter of the cohort (25.6%). Their all-cause mortality was significantly increased [HR: 1.22 (1.15-1.29)], with much of the increase contributed to by the inactive (HR: 1.27 (1.17-1.37)), relative to the reference group with sUA level of 5-6 mg/dL. When they were fully active, mortality risks did not increase, but decreased by 11% (HR: 0.89 (0.82-0.97)), reflecting the benefits of being active was able to overcome the adverse effects of high sUA. Given the same high sUA, a 4-6 years difference in life expectancy was found between the active and the inactive. Conclusions: Physical activity is a valuable alternative to pharmacotherapy in its ability to reduce the increases in mortality risks from high sUA. By being fully active, exercise can extend life span by 4-6 years, a level greater than the 1-4 years of life-shortening effect from high sUA.
AB - Background: High serum uric acid (sUA) has been associated with increased mortality risks, but its clinical treatment varied with potential side effects. The role of physical activity has received limited attention. Methods: A cohort, consisting of 467 976 adults, who went through a standard health screening programme, with questionnaire and fasting blood samples, was successively recruited between 1996 and 2008. High sUA is defined as uric acid above 7.0 mg/dL. Leisure time physical activity level was self-reported, with fully active defined as those with 30 min per day for at least 5days a week.National death file identified 12 228 deaths with a median follow-up of 8.5 years.Cox proportional model was used to analyse HRs, and 12 variables were controlled, including medical history, life style and risk factors. Findings High sUA constituted one quarter of the cohort (25.6%). Their all-cause mortality was significantly increased [HR: 1.22 (1.15-1.29)], with much of the increase contributed to by the inactive (HR: 1.27 (1.17-1.37)), relative to the reference group with sUA level of 5-6 mg/dL. When they were fully active, mortality risks did not increase, but decreased by 11% (HR: 0.89 (0.82-0.97)), reflecting the benefits of being active was able to overcome the adverse effects of high sUA. Given the same high sUA, a 4-6 years difference in life expectancy was found between the active and the inactive. Conclusions: Physical activity is a valuable alternative to pharmacotherapy in its ability to reduce the increases in mortality risks from high sUA. By being fully active, exercise can extend life span by 4-6 years, a level greater than the 1-4 years of life-shortening effect from high sUA.
UR - http://www.scopus.com/inward/record.url?scp=84945187095&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84945187095&partnerID=8YFLogxK
U2 - 10.1136/annrheumdis-2014-205312
DO - 10.1136/annrheumdis-2014-205312
M3 - Article
C2 - 25053714
AN - SCOPUS:84945187095
SN - 0003-4967
VL - 74
SP - 2034
EP - 2042
JO - Annals of the Rheumatic Diseases
JF - Annals of the Rheumatic Diseases
IS - 11
ER -